i think i have an answer to why and how gnbt is going to
i think i have an answer to why and how gnbt is going to spin off a major NASDAQ company when they are really worth only about 40 million and they are asking for an s1 that will give that much to stay alive......and the subsequent question by zoli from Germany that insisted on understanding why give away half of the company just to make this happen.....
generex had ae37 from way after they acquired antigen express....ae37 showed some promise...but with management the way they were, they did not really do anything with it....here comes Merck....they were making about 10 million a quarter on keytruda....but this miracle drug was not effective in treating triple negative affected women (and men)....so they saw the likelihood of ae37 in helping this cause, since some of the scientists involved with the discovery of ae37 had some merck origins (i don't remember whom, maybe rjs can chime on this)...
so when merck comes and offers generex to do a collaborative offer for the ae37.....the valuation of antigen express was raised high, very high....its all potential, nothing else...
Merck can corner the market on breast cancer if they can see good results with ae37.....they can do 15 billion a quarter on keytruda/ae37, if not more...
what does generex get out of this....ae37 works....Ii key peptide technology works....companies from all over the world want to use the tech for making vaccines, for different kinds of cancer (Shenzen) and infectious diseases...
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...
Continue Reading
Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....
Continue Reading
Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...
Continue Reading
History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...
Continue Reading
A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...
Continue Reading
Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...
Continue Reading
AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...
Continue Reading
Top 5 Most Recently Viewed Articles
Recent Share Transactions at Danish Aerospace Company A/S In a significant update for investors and stakeholders, Danish Aerospace Company A/S has announced recent transactions involving their shares by individuals in managerial positions and those closely associated with them. This announcement reflects compliance with the Market Abuse Regulation (EU) no. 596/2014,...
Continue Reading
A Roadway Overhaul in Del Mar A cool $57 million. That’s the ticket Skanska bought to scoop up the El Camino Real project in Del Mar, California. Think of it as a road facelift, a necessary one—it includes bulking up the corridor to four lanes and swapping in a spanking new San Dieguito River Bridge, taking the place of an old rascal that's been around for 84 years....
Continue Reading
Home Depot's Recent Options Trading Activity Recent activities in the world of finance have caught the attention of investors and analysts alike, particularly surrounding Home Depot. Our examination of the options market has unveiled an intriguing trend with significant bearish movements. With a thorough dive into the options history of Home Depot (HD), we identified 35...
Continue Reading
Boardroom Styling Lounge Introduces New Membership Plan Boardroom Styling Lounge, a prominent name in the men's grooming industry, has refreshed its membership program as part of its ongoing anniversary celebrations. This initiative reflects the company's dedication to adapting to the needs of modern men while maintaining exceptional service quality. Understanding...
Continue Reading
Key Financial Highlights for CNA Financial's Third Quarter CNA Financial Corporation (NYSE: CNA) has released its financial results for the third quarter of 2024, showcasing robust performance across various sectors. The net income reached a commendable $283 million, translating to $1.04 per share. This is a notable increase from the previous year's quarter, where the net...
Continue Reading